GlassScriptPhysician profile
Sandra Charnley
NPI 1528570983
$2,075.96
in general payments reported to CMS, 2019-2025
29 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $796 · 2022: $438 · 2023: $212 · 2024: $382 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $483.63 | 2023-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $312.93 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $200.98 | 2022 | |
| Abbvie INC. | $148.11 | 2021-2024 | |
| Novo Nordisk INC | $123.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.48 | 2021 | |
| Lilly USA, LLC | $74.87 | 2021 | |
| Scilex Pharmaceuticals INC. | $71.91 | 2023-2025 | Ztlido |
| Merck Sharp & Dohme LLC | $69.08 | 2021 | |
| Pfizer INC. | $54.15 | 2021 | |
| Amgen INC. | $54.12 | 2021-2023 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $51.24 | 2021-2023 | Shingrix, Arexvy |
| Grt US Holding, INC. | $43.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.79 | 2021 | |
| Amarin Pharma, INC. | $31.90 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $21.60 | 2024 | Qutenza |
| Esperion Therapeutics, INC. | $20.07 | 2021 | |
| Nalu Medical, INC. | $19.97 | 2024 | Nalu Neurostimulation System |
| Arbor Pharmaceuticals, INC. | $19.83 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.70 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.91 | 2021 | |
| Ibsa Pharma INC. | $15.99 | 2023 | Tirosint, Licart |
| Adlon Therapeutics L.P. | $15.14 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.76 | 2021 | |
| Abbott Laboratories | $13.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.13 | 2021 | |
| Astellas Pharma US INC | $12.45 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Charnley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.